Phase I trial of mesencephalic astrocyte-derived neurotrophic factor (MANF) in patients with Parkinson's disease.

Trial Profile

Phase I trial of mesencephalic astrocyte-derived neurotrophic factor (MANF) in patients with Parkinson's disease.

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 14 May 2015

At a glance

  • Drugs Mesencephalic astrocyte-derived neurotrophic factor (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions
  • Most Recent Events

    • 14 May 2015 This trial in Parkinson's disease appears to have been withdrawn prior to enrolment, as Amarantus BioScience Holdings is targeting retinitis pigmentosa for first-in-man studies of mesencephalic astrocyte-derived growth factor, as reported in a media release.
    • 09 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top